| abstract |
(R) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, their salt forms and with the processes for the commercial scale production of these compounds with sufficient purity and quality for use in pharmaceutical compositions for the treatment of diseases mediated by the modulation of neuronal nicotinic acetylcholine receptors (NNR). Claim 1: Mono-L-malate of (R) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, or a hydrate or solvate thereof . Claim 2: Hemigalactarate of (R) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, or a hydrate or solvate thereof. Claim 3: (R) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine oxalate, or a hydrate or solvate thereof. Claim 4: Di-p-toluoyl-D-tartrate of (R) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, or a hydrate or solvate of him. Claim 5: (R) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, or a pharmaceutically acceptable salt thereof substantially free of (S) -3 - ((E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine. Claim 16: A compound selected from: (R) -2- (1- (tert-butoxycarbonyl) pyrrolidin-3-yl) diethyl malonate; (R) -2- (1- (tert-Butoxycarbonyl) pyrrolidin-3-yl) malonic acid; Tert-butyl (R) -3- (2-hydroxyethyl) pyrrolidine-1-carboxylate; and tert-butyl (R) -3- (2-iodoethyl) pyrrolidine-1-carboxylate. |